|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue: | |||||
| Collaboration Revenue | |||||
| Grant Revenue | |||||
| Total Revenue | |||||
| Operating Expenses: | |||||
| General and Administrative | |||||
| Research and Development | |||||
| Collaboration Credits | |||||
| Change in Fair Value of Contingent Consideration | |||||
| Total Operating Expenses | |||||
| Operating (Loss) Income Before Other Income (Expense), Net | |||||
| Other Income, Net: | |||||
| Change in Fair Value of Warrant Liability | |||||
| Gain on Disposal of Fixed Assets | |||||
| Impairment of Intangible Assets | |||||
| Loss on Disposal of Fixed Assets | |||||
| Interest Income | |||||
| Interest Expense | |||||
| Other (Expense) Income, Net | |||||
| Total Other Income, Net | |||||
| (Loss) Income Before Income Tax Expense | |||||
| Income Tax Benefit (Expense) | |||||
| Net (Loss) Income | |||||
| Net Loss Attributable to Common Shareholders, basic | |||||
| Unrealized (Loss) Gain on Marketable Securities | |||||
| Foreign Currency Translation Adjustments | |||||
| Comprehensive (Loss) Income | |||||
| Net (Loss) Income Attributable to Common Shareholders, basic | |||||
| Net (Loss) Income Attributable to Common Shareholders, diluted | |||||
| Net (Loss) Income per Common Share - Basic (in usd per share) | |||||
| Weighted Average Shares Outstanding - Basic (in shares) | |||||
| Net (Loss) Income per Common Share - Diluted (in usd per share) | |||||
| Weighted Average Shares Outstanding - Diluted (in shares) | |||||
Loading...